Stand up for Biopharma in Maryland
Proposed legislation in Annapolis is threatening the growth and development
of biopharma companies across the state of Maryland.
To combat these threats, we created a comprehensive policy report which includes:
At the Maryland Chamber, we believe in a robust free enterprise system
to support the biopharma and biohealth industry.
This guide will provide you with valuable tools and resources not only to learn more about the bills impacting your business, but also how you can get involved through the Maryland Chamber.
Download the Biopharma Policy Report Today.
Join Our Health Care and Biopharma Policy Committee
To establish a unified voice and message for the biopharma industry,
the Maryland Chamber created the Health Care and Biopharma Policy
Committee to bring together leaders in the industry to advocate for
meaningful legislation that promotes the industry’s regional growth
The Health Care and Biopharma Committee covers all health care issues, including cost factors, mandated health benefit demands and regulatory oversights and requirements relative to improving Maryland’s current market-based health care system to control costs and improve affordable access to coverage. Additionally, we address issues regarding legislative interaction in pharmacological discovery, development processes, and related areas.
During the 2019 legislative session, the Maryland Chamber worked hard to review and advocate for or against important bills that impact research and development, pharmaceutical pricing, and corporate tax rates.
Last year alone, legislators introduced 3,101 bills and 26 joint resolutions during the 2018 session—1,269 from the Senate and 1,832 from the House. In conjunction with our Legislative and Policy Committees, we reviewed 325 bills, tracking and testifying on 125 with significant foreseeable impacts on Maryland’s businesses and industries.
"Maryland Chamber’s dedication to their members’ success is like having an extension of our very own government and public aﬀairs team. Their commitment to the state has beneﬁted not only the life sciences and manufacturing industries, but also the community as a whole.”
Chris Frech, SVP Global Affairs, Emergent BioSolutions
On the front line of developing lifesaving vaccines and unparalleled
innovation, the biopharma and life sciences industry is vital to
the future of our state—and our planet.
This report enables biopharma business leaders, small and large, to stay on top of important legislation and make a difference in Annapolis.
Download the Biopharma Report to learn more about proposed legislation and how you can get involved today.